Bradford.nhs.uk

Yorkshire and the Humber Specialised Commissionning Group
Board Meeting - 24th September 2010
Decision Summary for PCT Boards

1. Policies:

General Commissioning Policies for Medicines and Treatments
The following four policies were approved for adoption by the SCG:-

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours - To be not routinely funded, in accordance with Capecitabine for the treatment of advanced gastric cancer - To be routinely funded in Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia - To be routinely fun Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer - Update to regional policy 08/10 to reflect recently published Evidenced-Based Commissioning (EBC) - Policies
The following policies were approved for adoption by the SCG (category 2 in the EBC list)
Armour Thyroid (thyroid tablets USP, Forrest Pharmaceuticals) and other non – UK licensed products - (Hypothyroidism) Bevacizumab (Avastin, Roche) – (Metastatic Colorectal Cancer) Botulinum toxin type A (botox, Allergan; and all other brands) – (Hyperhidrosis) Botulinum toxin A (Available as Botox (allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma) – (Overactive Bladder) Botulinum toxin type A (Available as Botox (Allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma) – (Prophylaxis of Migraine) Botulinum toxin A (Available as Botox (Allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma Ltd) – (Anal Tissues) Cetuximab (Erbitux, Merck) – (Metastatic Colorectal Cancer) Co-careldopa 2000mg/500mg intestinal gel for administration via PEG tube – (Parkinson’s Disease) Penile Prostheses – (Erectile Dysfunction) Gemcitabine IV infusion (Gemzar, Eli Lilly) Capecitabine 150mg or 500mg tablets (Xeloda, Roche) – (Pancreatic Cancer) Infliximab – (Hidradenitis Supportiva) C:\DOCUME~1\whitej\LOCALS~1\Temp\DecisionSummarySheet240910.doc 1 Mecasermin (Increlex, Ipsen) – (Growth Failure) Sacral Nerve Stimulation [SNS] (Sacral Nerve Neuromodulation) – (Urinary retention/urinary urge incontinence/faecal incontinence/chronic constipation) Spinal Cord Stimulation (neuromodulation) – (Intractable Chronic Pain) (b)
The following policies were approved for adoption by the constituent PCTs of the Yorkshire &
the Humber SCG unless a PCT is able to inform the SCG why they should not adopt a specific
policy (category 3 in the EBC list).
Fesoterodine 4mg or 8mg tablets (Tovias, Pfizer Ltd) – (Overactive Bladder Syndrome)
Testosterone Patch 300mg/24 hours twice weekly (Intrinsa, Proctor & Gamble Pharmaceuticals –
(Hypoactive Sexual Disire Disorder)
Ivabradine (Procoralan, Servier) – (Angina)
Liraglutide 6mg/mL pre-filled pen (Victoza, Novo-Nordisk – (Type 2 Diabetes Mellitus)
Nebivolol 5mg tablets (Nebilet, A, Menarini Pharma UK – (Chronic Heart Failure)
NuvaRing (11.7 mg etonogestrel and 2.7 mg ethinylestradiol) Organon – (Contraception)
Prostaglandin Analogues (latanoprost, bimatoprost, travaprost, tafluprost) – (Glaucoma)
Proton Pump Inhibitors (Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole) – (Dyspesia)
Ranolazine Modified release tablets (Ranexa; A Menarini Pharma UK) – (Angina)
Retapamulin 1% - (Skin Infections)
Sitagliptin 100mg tablets (Januvia, MSD) – (Diabetes)
Solifenacin 5mg and 10mg (Vesicare, Astellas Pharma Ltd) – (Urge Incontinence)
Buprenorphone/naloxone (Suboxone/Schering Plough – (Opioid Dependence)
Prolonged release oxycodone & naloxone tablets (Targinact, Napp Pharmaceuticals) – (Severe Pain)
Ulipristal Acetat 30mg (EllaOne HRA Pharma UK) – (Contraception)
Vildagliptin 50mg tablets (Galvus, Novartis) – (Diabetes)
Reimbursement of Living Donor Expenses Policy
This policy recommended by the Yorkshire & the Humber Renal Network was approved
for adoption by the SCG.
2. Governance
Yorkshire & the Humber SCG Annual Report 2009/10
It was agreed that:- The annual report be presented to PCT Boards.
Strengthening SCG Board Governance Arrangements

**PCT Boards are recommended to adopt the Establishment Agreement and Scheme of
Delegation in respect of the Yorkshire and the Humber Specialised Commissioning Group**.
C:\DOCUME~1\whitej\LOCALS~1\Temp\DecisionSummarySheet240910.doc 2

Source: http://www.bradford.nhs.uk/wp-content/uploads/2010/11/Board-meeting-231110-Item-12c-Yorkshire-and-Humber-SCG-decision-sheet-Sep-10.pdf